ClinicalTrials.gov
public full text
Public Domain
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma#844069
- CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms#967250
- CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors#1044888
- CAR T Cell Immunotherapy for Pancreatic Cancer#432902
- Phase I Study of TAS-106 in Combo With Carboplatin#869287
Record · ID 1047972
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive